Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025

Transgene (Euronext Paris: TNG),a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will presenta poster highlighting in-depth analysis of the neoantigen-specific T cell response from the randomized Phase I trial of its individualized therapeutic cancer vaccine, TG4050, at the 40 thAnnual Meeting of the Society for Immunotherapy of Cancer(SITC).SITC will take place November 5 to 9, 2025, in National Harbor, Maryland, USA. Poster...

Strasbourg, 03/10/2025 (informazione.news - comunicati stampa - economia)

a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present SITC will take place November 5 to 9, 2025, in National Harbor, Maryland, USA.

Poster details

The abstract will be available on the SITC website on November 4, 2025, at 9 a.m. ET.

TG4050 is an individualized immunotherapy being developed for solid tumors that is based on Transgene’s ® technology and powered by NEC’s longstanding artificial intelligence (AI) expertise. TG4050 is being evaluated in a randomized multicenter Phase I/II clinical trial as a single agent in the adjuvant treatment of HPV-negative head and neck cancers (NCT04183166).

Transgene previously presented in a rapid oral presentation at the ASCO conference in June 2025, that , comparing favorably to the observational arm which saw 3 out of 16 patients relapse during the same time period.

Transgene and NEC are , which is currently enrolling patients.

***

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a portfolio of viral vector-based immunotherapeutics. TG4050, the first individualized therapeutic vaccine based on the platform is the Company’s lead asset, with demonstrated proof of principle in patients in the adjuvant treatment of head and neck cancers. The Company has other viral vector-based assets, including BT-001, an oncolytic virus based on the Invir.IO® viral backbone, which is in clinical development. The Company also conducts innovative discovery and preclinical work, aimed at developing novel immunotherapies.
With Transgene’s platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.
Additional information about Transgene is available at: www.transgene.com
Follow us on social media: X (formerly Twitter): @TransgeneSA — LinkedIn: @Transgene — Bluesky: @Transgene

Attachment